France's Synerlab buys Spain's Alcalá Farma.
The purchase has been made through the Frances Fund. Ardian to which the biotech company SynerlabThe 21 Partners group, which like Ardian is a shareholder in Synerlab, has also participated in the financing of the acquisition.
Alcalá Farma está especializada en el desarrollo de formulaciones registradas, que representan cerca del 40% de sus ventas totales, valoradas en €25 M, y son la palanca clave para su crecimiento futuro.
Its portfolio includes a wide range of finished dosage forms, such as injectable, oral or topical products.
The purchase will allow Synerlab, which already has 5 plants in France, to start expanding in the European market, first entering Spain. In addition to a broad and complementary product portfolio, with a strong presence of soft gelatin capsules and sticks.
With an average annual growth of around 8%, Synerlab is benefiting from the trend of pharmaceutical groups increasingly outsourcing their manufacturing activities and repatriating production to Europe for better quality control, as well as from the growing demand for generics.
Mint Labs and health Search seek funding from Capital cell
Health Startups Mint Labs and Health Search have decided to opt for crowdfunding to get funding and have done so on the Capital cell platform.
Mint Labs is a solution for early prediction of mental illnesses, which are often difficult to diagnose.
It can do this thanks to a cloud-based platform for the analysis and quantification of 3D data without the need to invest in data processing, hardware or software. This platform, which they call CloudN, can not only take images but can also receive medical images acquired in clinical and pre-clinical trials from pharmaceutical companies, hospitals or imaging centres.
So far the company has raised €62,175 and still has 21 days left to reach its target of €150,000.00.
HealthSearch is a pioneering company in services for the digitisation of the biomedical and pharma industry. Its multidisciplinary team combines experience both in the world of online marketing and in the medical industry itself, which allows it to offer immense added value to companies in the sector, mainly to independent professionals and SMEs in the biomedical sector, which at European level represents a market of 18 billion euros for 2017, in the digitisation of clinical processes.
So far the company has raised €10,616 of their €75,000 target and they still have 5i days to go.
El cdti convoca una misión internacional de cooperación tecnológica con el Departamento indio de Biotecnología – DBT
The objective of the mission is to facilitate contacts between companies and entities of both countries in the Biotechnology and Life Sciences sector, identification of possible collaborations or ideas for R&D projects between entities of both countries, technical visits to facilities and centres of interest in India.
CDTI gestiona además, un programa de cooperación con el Departamento indio de Biotecnología al través del cual se promueven y financian proyectos de I+D competitiva entre empresas españolas y entidades indias.
The event will take place between 8 and 11 February 2016.
If you are looking for funding for the biotech sector, please contact us. Abra-Invest has a team of experts in alternative financing with many years of experience in the biotech sector. Call + 34 946424142 or fill in the contact form.
Other posts that may interest you
Biotech operations: Minoryx, Suanfarma, Ability Pharma and Oryzon Genomics
Biotech investment news September 2015: CaixaIpulse, Sanifit and Centauri Biotech